Fig. 3From: The 2021–2022 position of Brazilian Diabetes Society on diabetic kidney disease (DKD) management: an evidence-based guideline to clinical practice. Screening and treatment of hyperglycemia, arterial hypertension, and dyslipidemia in the patient with DKDSource: Adapted from Bertoluci et al. [64]. *Dose adjustment required, except for linagliptin. **Only if GFR > 15 mL/min/1.73 m2Management of hyperglycemia in severe DKD.Back to article page